Medullary Carcinoma

Slide 1 · MEDULLARY THYROID CARCINOMA

C-cell neuroendocrine malignancy | Morphology, RET genetics, MEN2 and clinical correlation

Pathology teaching lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Locate medullary carcinoma within the thyroid tumor spectrum.

Relate RET activation and C-cell biology to hereditary and sporadic disease.

Recognize the characteristic gross and microscopic morphology.

Interpret calcitonin, CEA, MEN2 phenotypes, and inherited-risk clues.

Slide 3 · A tumor of parafollicular C cells

Medullary carcinoma arises from the thyroid parafollicular C-cell lineage.

The neoplastic cells retain neuroendocrine differentiation.

This lineage differs from the follicular cells forming most other thyroid carcinomas.

C cell

Colloid-filled follicle

Schematic

Slide 4 · Two thyroid cell lineages, distinct tumor phenotypes

Follicular epithelial lineage

Parafollicular C-cell lineage

Follicular architecture and thyroid-hormone synthesis

Calcitonin secretion and neuroendocrine differentiation

Papillary and follicular carcinomas

Medullary carcinoma

Histologic and genetic classification differs

RET alterations are central to MTC biology

Slide 5 · Recognizing the medullary phenotype

C-cell origin

Calcitonin production

Neuroendocrine cytology

Often stromal amyloid

Slide 6 · Where medullary carcinoma fits in thyroid cancer

~5%

Of thyroid carcinomas in the Robbins overview

The majority of other thyroid carcinomas derive from follicular epithelial cells.

Despite its relative rarity, medullary carcinoma is clinically significant because of hereditary predisposition and endocrine secretion.

Slide 7 · Most cases are sporadic; A substantial minority are inherited

70% Sporadic

30%

MEN2-associated

Approximately 70% as sporadic.

The remaining approximately 30% arise in a hereditary MEN2 setting.

Slide 8 · Age at presentation reflects genetic context

Sporadic MTC

MEN2-associated MTC

Usually a tumor of adulthood

Frequently occurs at a younger age

Peak incidence in the 40s–50s

May appear during the first decade

Often a solitary lesion

Often multifocal or bilateral

Slide 9 · Calcitonin: The normal C-cell secretory product

Rise in serum calcium

Physiologic C-cell response

Calcitonin secretion

Lowering of calcium

Calcitonin is secreted in response to hypercalcemia.

Its effects oppose calcium elevation through bone and renal pathways.

Slide 10 · Calcitonin reduces osteoclast activity

Calcitonin

Inhibition of osteoclast activity

Less bone resorption

Reduced calcium release

Osteoclast inhibition is a component of normal calcitonin action.

The endocrine product remains a tissue-lineage marker in MTC.

Slide 11 · Calcitonin affects renal calcium handling

Calcitonin

Lower tubular calcium reabsorption

Greater urinary calcium loss

Calcium-lowering effect

Renal tubular calcium transport as a normal calcitonin target.

Slide 12 · Marked calcitonin does not imply prominent hypocalcemia

Tumor may secrete abundant calcitonin

Hypocalcemia is generally not a prominent clinical feature

Biochemical marker abundance is not equivalent to a clinically overt hormone-effect syndrome.

Do not infer symptomatic hypocalcemia solely from an elevated tumor marker.

Slide 13 · MTC can produce additional endocrine products

Neoplastic C cell

Calcitonin

Other secretory products

Variable syndromes

Reported products include serotonin, corticotropin and vasoactive intestinal peptide (VIP).

Different secreted products can explain distinct paraneoplastic presentations.

Slide 14 · Secretory phenotype and local tumor growth are separate

Local tumor behavior

Endocrine secretion

Neck mass, dysphagia, hoarseness

Raised circulating calcitonin

Infiltration of surrounding tissue

Occasional diarrhea from VIP

Structural symptoms may dominate

Occasional Cushing syndrome from corticotropin

Slide 15 · RET is a receptor tyrosine kinase proto-oncogene

RET receptor

Normal signal input

Growth / differentiation signaling

Regulated cellular response

RET as a receptor tyrosine kinase.

RET signaling participates in normal growth and differentiation.

Slide 16 · Oncogenic RET mutations bypass normal regulation

Normal RET: Activation is ligand-dependent

Mutant RET: Signaling can become constitutive

Gain-of-function mutations activate oncogenic signaling.

This is central to MEN2-associated tumorigenesis.

Slide 17 · RET activation in sporadic medullary carcinoma

Activating RET point mutations participate in sporadic tumorigenesis.

The altered gene is present in the neoplastic cells rather than necessarily inherited.

A sporadic clinical presentation does not reliably exclude a germline RET variant.

Slide 18 · Germline RET mutations confer inherited susceptibility

Germline RET variant

RET signaling predisposition

C-cell proliferative lesions

Medullary carcinoma

MEN2-associated MTC develops in a hereditary RET mutation context.

Early recognition permits preventive management of mutation carriers.

Slide 19 · Somatic and germline RET alterations are not interchangeable

Somatic RET alteration

Germline RET alteration

Acquired by tumor-cell lineage

Present from conception across tissues

Typically informs tumor biology

Defines inherited predisposition

Does not itself establish family risk

Has implications for relatives and screening

Slide 20 · Molecular results must be interpreted with clinical context

A thyroid tumor with RET activation may be sporadic or hereditary.

An apparently negative family history does not exclude inherited risk.

Germline assessment addresses a different question from tumor-only mutation testing.

Slide 21 · MEN2: A hereditary endocrine neoplasia spectrum

RET-associated MEN2

MEN2A

MEN2B

Familial MTC phenotype

The clinical constellation determines the syndrome designation.

Medullary thyroid carcinoma is the unifying thyroid manifestation.

Slide 22 · MEN2A links three endocrine compartments

MEN2A

Medullary thyroid carcinoma

Pheochromocytoma

Parathyroid hyperplasia

Classical MEN2A is also called Sipple syndrome.

The thyroid tumor is typically multicentric.

Slide 23 · MTC in MEN2A is frequently multicentric

Medullary carcinomas arise in almost all affected individuals, as.

Multiple foci and C-cell hyperplasia commonly coexist in the thyroid.

The multiplicity provides a morphologic clue to hereditary predisposition.

Slide 24 · Pheochromocytoma is part of the MEN2A phenotype

Pheochromocytoma in about 40%–50% of MEN2A patients.

Pheochromocytomas can be bilateral and sometimes extra-adrenal.

A thyroid MTC diagnosis warrants attention to the broader MEN2 phenotype.

Slide 25 · Parathyroid disease distinguishes MEN2A from MEN2B

MEN2A may feature parathyroid hyperplasia and hypercalcemia.

Parathyroid manifestations in approximately 10%–20%.

MEN2B does not characteristically include primary hyperparathyroidism.

Slide 26 · MEN2B combines MTC with extra-thyroid stigmata

MEN2B

Medullary thyroid carcinoma

Pheochromocytoma

Mucosal neuromas / marfanoid habitus

MEN2B-associated MTC may be particularly aggressive.

Neuromas or ganglioneuromas occur across several sites.

Slide 27 · MEN2B phenotype: Neuromas and marfanoid features

Neuromas or ganglioneuromas may involve oral mucosa, skin, eyes, respiratory tract, and gut.

Marfanoid body habitus includes elongated skeletal proportions.

The nonthyroid phenotype can suggest the diagnosis before an obvious neck mass.

Slide 28 · MEN2A versus MEN2B

MEN2A

MEN2B

MTC and pheochromocytoma

MTC and pheochromocytoma

Parathyroid hyperplasia may occur

Primary hyperparathyroidism usually absent

C-cell hyperplasia common

MTC often more aggressive

RET gain-of-function mutations

Distinct RET activating mutation spectrum

Slide 29 · MEN1 and MEN2 should not be conflated

MEN1 syndrome

MEN2 syndrome

MEN1 tumor-suppressor gene

RET proto-oncogene activation

Parathyroid, pancreatic, pituitary tumors

Medullary thyroid carcinoma is central

Different genetic and endocrine spectrum

Pheochromocytoma / neuroma phenotypes

Slide 30 · Familial MTC may lack overt extra-thyroid manifestations

Some families have inherited RET variants with apparently isolated medullary carcinoma.

The absence of obvious pheochromocytoma or parathyroid disease does not remove hereditary risk.

Robbins recommends examining the wider MEN2 phenotype carefully.

Slide 31 · C-cell hyperplasia is an inherited-risk clue

C-cell hyperplasia often accompanies syndromic medullary carcinoma.

It is considered a precursor lesion in the familial setting.

It is usually absent in purely sporadic lesions.

C cell

Colloid-filled follicle

Schematic

Slide 32 · A stepwise C-cell lesion model

RET-associated predisposition

C-cell hyperplasia

Early MTC foci

Clinically apparent MTC

The schematic illustrates the hereditary setting.

This does not define universal temporal thresholds for every tumor.

Slide 33 · The contralateral lobe can contain a diagnostic clue

Clusters of conspicuous C cells away from the dominant tumor suggest a field predisposition.

Check the opposite thyroid lobe, not only the dominant lesion.

Simplified thyroid schematic

Slide 34 · Sporadic MTC often forms a solitary nodule

A single dominant thyroid nodule is characteristic of sporadic disease.

Clinical and genetic evaluation is still necessary because morphology is not absolute.

Simplified thyroid schematic

Slide 35 · Hereditary MTC is often bilateral or multifocal

Multicentricity and bilaterality support a hereditary context.

Search the intervening and contralateral parenchyma for C-cell hyperplasia.

Simplified thyroid schematic

Slide 36 · Gross appearance: Firm, pale gray-to-tan tumor

The cut surface is typically pale gray to tan.

Infiltrative borders may be apparent; Tumors often lack a distinct connective-tissue capsule.

Gross appearance — schematic

Slide 37 · Infiltrative architecture matters more than encapsulation

MTC is usually infiltrative rather than cleanly encapsulated.

Larger tumors may extend through the thyroid capsule.

Gross appearance — schematic

Slide 38 · Large lesions may show hemorrhage and necrosis

Hemorrhage and necrosis can occur in larger neoplasms.

These are gross changes, not required diagnostic criteria.

Gross appearance — schematic

Slide 39 · Microscopy: A neuroendocrine-appearing population

Cells range from polygonal to spindle-shaped.

Cytologic variation does not eliminate a shared C-cell lineage.

Schematic; Not a histologic specimen

Slide 40 · Nested arrangement is a typical growth pattern

Tumor cells are often arranged in compact nests.

Intervening stroma may contain characteristic amyloid.

Schematic; Not a histologic specimen

Slide 41 · Trabecular growth is also encountered

Elongated ribbons or trabeculae may be present.

The architectural spectrum requires integration with cytology and secretory phenotype.

Schematic; Not a histologic specimen

Slide 42 · Follicle-like structures can occur in medullary carcinoma

MTC sometimes produces follicle-like structures.

Architecture alone may therefore be misleading for cell-lineage assignment.

Schematic; Not a histologic specimen

Slide 43 · Neuroendocrine chromatin supports recognition

Stippled nuclear chromatin and round nuclei.

Nuclear findings support—not independently define—the diagnosis.

Schematic; Not a histologic specimen

Slide 44 · Stromal amyloid is a characteristic clue

Pink, extracellular amorphous material can lie between tumor-cell nests.

Amyloid is frequently present but not mandatory in every specimen.

Amyloid-rich extracellular stroma

Schematic; Not H&E

Slide 45 · The amyloid is derived from calcitonin polypeptides

MTC cell

Calcitonin-polypeptide secretion

Extracellular peptide deposition

Stromal amyloid

The defining relation explains the association between calcitonin secretion and stromal amyloid.

Slide 46 · Calcitonin is demonstrable in tumor cells and stroma

Neoplastic cells

Amyloid-rich stroma

Calcitonin by immunohistochemistry

Calcitonin can be demonstrated in associated amyloid

Corroborates C-cell neuroendocrine identity

Connects extracellular material to tumor secretion

Slide 47 · Electron-dense secretory granules explain endocrine output

Electron microscopy reveals membrane-bound, electron-dense granules.

The granules store calcitonin and related secretory peptides.

Secretory granules

Schematic; Not a histologic specimen

Slide 48 · Morphologic diagnosis combines several layers of evidence

C-cell phenotype

Variable nests or trabeculae

Neuroendocrine chromatin

Amyloid / calcitonin evidence

Slide 49 · MTC differs from follicular-derived thyroid carcinomas

Follicular-derived carcinomas

Medullary carcinoma

Follicular epithelial lineage

Parafollicular C-cell lineage

Genetic context includes BRAF or RAS pathways

RET activation is prominent

Thyroid hormone lineage

Calcitonin-producing lineage

Papillary nuclear features or follicular invasion

Neuroendocrine cytology; Stromal amyloid

Slide 50 · A neck mass is a common sporadic presentation

Patients with sporadic MTC often present with a thyroid or neck mass.

Some lesions are clinically silent until they enlarge.

The clinical appearance alone is not sufficient to determine molecular or hereditary subtype.

Slide 51 · Dysphagia and hoarseness reflect local effects

Thyroid tumor growth

Local mass effect or involvement

Swallowing / voice symptoms

Clinical assessment

Dysphagia and hoarseness may accompany a cervical mass.

These symptoms reflect anatomic consequences rather than peptide secretion.

Slide 52 · VIP secretion can produce a diarrheal syndrome

MTC secretory activity

VIP production in some tumors

Intestinal secretory response

Diarrhea

Diarrhea can be a paraneoplastic clue to medullary carcinoma.

Most tumors should not be assumed to produce this phenotype.

Slide 53 · Corticotropin secretion may cause Cushing syndrome

Ectopic corticotropin production

Adrenal glucocorticoid stimulation

Excess cortisol effect

Cushing syndrome

The presentation is peptide-mediated rather than caused directly by the thyroid mass.

Slide 54 · A calcitonin assay has diagnostic relevance

Calcitonin is a core measurable product of differentiated C-cell tumors.

Serum calcitonin as important in diagnosis.

Interpret the laboratory result in the full clinical and pathologic context.

Slide 55 · Calcitonin also supports postoperative surveillance

Surgery for MTC

Measure circulating calcitonin

Track postoperative values

Assess possible persistence / recurrence

The role of calcitonin in follow-up.

Do not substitute unverified cutoffs or kinetics for clinical guidance.

Slide 56 · CEA is a complementary tumor-associated marker

MTC cells may release carcinoembryonic antigen (CEA).

CEA contributes to presurgical estimation of disease burden.

CEA is also helpful when calcitonin secretion is unusually absent.

Slide 57 · Calcitonin-negative MTC is an important caveat

Typical phenotype: Calcitonin-producing tumor

Rare phenotype: Calcitonin-negative tumor

A negative marker should not be treated as an absolute exclusion.

CEA and histologic context become especially useful in this setting.

Slide 58 · Germline RET testing changes family-level care

A 2015 recommendation for germline RET testing in all MTC patients.

An apparently sporadic tumor may have an inherited predisposition.

A confirmed germline variant informs family counseling and testing.

Slide 59 · Testing relatives turns a tumor diagnosis into prevention

Index patient with MTC

Identify germline RET variant

Evaluate at-risk relatives

Offer preventive management

Screening can identify carriers before a palpable thyroid cancer develops.

This is distinct from routine postoperative tumor-marker follow-up.

Slide 60 · Prophylactic thyroidectomy is mutation-informed

Asymptomatic RET carrier

Risk assessment by variant

Plan early thyroidectomy

Prevent clinically overt MTC

Operative timing depends on the specific RET mutation.

No particular age or codon threshold is asserted here without updated guideline verification.

Slide 61 · Prophylactic specimens may contain only microscopic disease

Resected thyroids may show C-cell hyperplasia alone.

Some contain small medullary microcarcinomas under 1 cm.

These findings illustrate detection before symptomatic tumor burden develops.

Simplified thyroid schematic

Slide 62 · RET inhibition is a molecular treatment principle

Oncogenic RET activity

RET tyrosine kinase inhibitor

Reduced kinase signaling

Therapeutic strategy

Development and clinical use of small-molecule RET inhibitors.

This is a mechanism overview, not a treatment-selection guideline.

Slide 63 · Case: Solitary nodule in an adult

CASE VIGNETTE

A 52-year-old patient presents with a firm thyroid nodule. Histology shows polygonal neuroendocrine-appearing cells and stromal amyloid.

INTERPRETATION QUESTION

What lineage and key measurable biomarker should be considered?

Medullary thyroid carcinoma of C-cell origin; Calcitonin is the principal biomarker.

Slide 64 · Case: Bilateral tumors and C-cell hyperplasia

CASE VIGNETTE

A younger patient has bilateral thyroid foci; C-cell hyperplasia is prominent in the background and contralateral gland.

INTERPRETATION QUESTION

Which molecular and family-level consideration follows?

Consider an inherited MEN2-associated germline RET predisposition and evaluate familial risk.

Slide 65 · Case: Mucosal neuromas with a thyroid lesion

CASE VIGNETTE

A patient has multiple oral mucosal neuromas, marfanoid habitus, and a thyroid tumor with calcitonin expression.

INTERPRETATION QUESTION

Which syndrome phenotype is most consistent?

MEN2B, associated with RET activation and medullary thyroid carcinoma.

Slide 66 · Case: Peptide-mediated diarrhea

CASE VIGNETTE

A patient with a neck mass develops unexplained secretory diarrhea; The thyroid biopsy shows a neuroendocrine tumor.

INTERPRETATION QUESTION

What paraneoplastic mechanism is supported by the source?

Ectopic production of VIP by some medullary carcinomas.

Slide 67 · Integrated clinicopathologic interpretation

Finding

Interpretation

Multifocal MTC + C-cell hyperplasia

Strong hereditary predisposition clue

Nests, stippled chromatin, amyloid

Supports C-cell neuroendocrine carcinoma

Calcitonin and CEA elevation

Biomarkers for disease evaluation

Neuromas / pheochromocytoma

Look for MEN2 syndrome spectrum

Slide 68 · What the pathologist should report and communicate

Establish the neuroendocrine C-cell phenotype using morphology and applicable ancillary findings.

Describe multiplicity, infiltration, and background C-cell changes where present.

Flag a possible hereditary phenotype when C-cell hyperplasia or multifocality is identified.

Communicate the rationale for genetic risk assessment without assuming a specific RET genotype.

Slide 69 · Reference and source scope

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 24: The Endocrine System. Medullary Carcinoma, pp. 992–993.

Same chapter: Thyroid Carcinomas (parent context); Multiple Endocrine Neoplasia, Type 2 (hereditary context).

Text adapted for teaching from the supplied robbins.md conversion; no original textbook figures embedded.

Guideline details, staging and contemporary therapeutic indications have not been independently updated.